12:00 AM
 | 
Apr 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

StemEx: Additional Phase II/III data

Additional data from the open-label, international Phase II/III ExCell trial in 101 patients with hematologic malignancies following myeloablative therapy who did not have a matched, family-related bone marrow donor showed that StemEx missed the secondary endpoints of reducing the mortality rate at 180 days post-transplantation (32.7% vs. 34.7%, p=0.39), the incidence of acute GvHD grades III-IV (19.4% vs. 16.9%, p=0.11) and the rate of neutrophil engraftment failure (8.1% vs. 14.5%, p=0.086) vs. a historical control group....

Read the full 360 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >